| Literature DB >> 29863657 |
Shukun Chen1, Amin El-Heliebi1, Julia Schmid1, Karl Kashofer2, Zbigniew T Czyż3, Bernhard Michael Polzer3, Klaus Pantel4, Thomas Kroneis5, Peter Sedlmayr1.
Abstract
Rare target cells can be isolated from a high background of non-target cells using antibodies specific for surface proteins of target cells. A recently developed method uses a medical wire functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies for in vivo isolation of circulating tumor cells (CTCs)1. A patient-matched cohort in non-metastatic prostate cancer showed that the in vivo isolation technique resulted in a higher percentage of patients positive for CTCs as well as higher CTC counts as compared to the current gold standard in CTC enumeration. As cells cannot be recovered from current medical devices, a new functionalized wire (referred to as Device) was manufactured allowing capture and subsequent detachment of cells by enzymatic treatment. Cells are allowed to attach to the Device, visualized on a microscope and detached using enzymatic treatment. Recovered cells are cytocentrifuged onto membrane-coated slides and harvested individually by means of laser microdissection or micromanipulation. Single-cell samples are then subjected to single-cell whole genome amplification allowing multiple downstream analysis including screening and target-specific approaches. The procedure of isolation and recovery yields high quality DNA from single cells and does not impair subsequent whole genome amplification (WGA). A single cell's amplified DNA can be forwarded to screening and/or targeted analysis such as array comparative genome hybridization (array-CGH) or sequencing. The device allows ex vivo isolation from artificial rare cell samples (i.e. 500 target cells spiked into 5 mL of peripheral blood). Whereas detachment rates of cells are acceptable (50 - 90%), the recovery rate of detached cells onto slides spans a wide range dependent on the cell line used (<10 - >50%) and needs some further attention. This device is not cleared for the use in patients.Entities:
Mesh:
Year: 2018 PMID: 29863657 PMCID: PMC6101176 DOI: 10.3791/56394
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355




|
|
|
| 5′-gtt cca ata tga ttc cac cc-3′ | 100 bp forward primer |
| 5′-ctc ctg gaa gat ggt gat gg-3′ | 100 bp reverse primer |
| 5′-agg tgg agc gag gct agc-3′ | 200 bp forward primer |
| 5′-ttt tgc ggt gga aat gtc ct-3′ | 200 bp reverse primer |
| 5′-agg tga gac att ctt gct gg-3′ | 300 bp forward primer |
| 5′-tcc act aac cag tca gcg tc-3′ | 300 bp reverse primer |
| 5′-aca gtc cat gcc atc act gc-3′ | 400 bp forward primer |
| 5′-gct tga caa agt ggt cgt tg-3′ | 400 bp reverse primer |